News

Public · Published

Canaccord Genuity maintains Bioventus at Buy, lowers price target to $18 from $19

Canaccord Genuity kept its Buy rating on Bioventus but lowered its price target to $18 from $19, a 5.3% decrease. The new target implies 36.9% upside from the Nov 2 close of $13.15.

Published:

Updated:

What happened

Canaccord Genuity kept its Buy rating on Bioventus but lowered its price target to $18 from $19, a 5.3% decrease. The new target implies 36.9% upside from the Nov 2 close of $13.15.

Confirmed

Global impact / market context

A lower price target still above the current share price signals the analyst sees less upside but keeps a positive view. Investors reading the Buy rating should note the reduced expected return rather than treat the rating alone as the full message.

Analyst inference

The target implies 36.9% upside from the $13.15 close, so the analyst still expects meaningful gains despite trimming expectations. That gap between the rating and the smaller target shapes how investors weigh the stock's potential return against its risks.

Analyst inference

What to watch

  1. Watch whether other analysts change their Bioventus ratings or price targets after Canaccord's move, since the article notes prior and future recommendations can be tracked. Confirmed
  2. Investors could compare the $18 target with the $13.15 close to judge expected upside, and check whether the company reports results that support the Buy case. Proposed
  3. A further cut to the target or a rating downgrade would weaken the positive view, while a target increase would suggest the analyst sees more upside than the current 36.9%. Analyst inference

Evidence

  • Original source link unavailable